Browsing by Author Johnston, Michael

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2014Assessing Risks to Non-Target Species during Poison Baiting Programs for Feral CatsBuckmaster, Anthony; Dickman, Christopher; Johnston, Michael; Biological Sciences; Biological SciencesAssessing Risks to Non-Target Species during Poison Baiting Programs for Feral Cats, PloS One, vol.9, 9, 2014,pp 1-7
2012Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST studyBoyer, Michael; Pavlakis, Nick; Abell, Fiona; de Souza, Paul; Horwood, Keith; Johnston, Michael; Millward, Michael; Rischin, Danny; Stein, Brian; Central Clinical School: Medicine; Northern Clinical School: MedicineEfficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study, Asia Pacific Journal of Clinical Oncology, vol.8, 3, 2012,pp 248-254
2013Induction brazing of type-I fiber Bragg gratings into kovar ferrules exploiting Curie transitionCanning, John; Cook, Kevin; Johnston, Michael; Niewczas, Pawel; Perry, Marcus; Chemistry; ChemistryInduction brazing of type-I fiber Bragg gratings into kovar ferrules exploiting Curie transition, IEEE Sensors Journal, vol.13, 2, 2013,pp 816-823
2012Mechanical strength of silica fiber splices after exposure to extreme temperaturesCanning, John; Cook, Kevin; Johnston, Michael; Niewczas, Pawel; Perry, Marcus; Chemistry; ChemistryMechanical strength of silica fiber splices after exposure to extreme temperatures, 22nd International Conference on Optical Fiber Sensors, vol.8421, 2012, pp. 8421AD-1-8421AD-4
2012A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancerClarke, Stephen; Pavlakis, Nick; Clingan, Philip R.; de Boer, Richard; Johnston, Michael; Michael, Michael; Concord Clinical School: Medicine; Northern Clinical School: MedicineA multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer, Oncology reports, vol.28, 3, 2012,pp 763-767